Who is on it, and how far along Every drug ChEMBL records acting on GRIA1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved2 Topiramate Topiramate SponsorJohnson & Johnson ModalitySmall molecule ActionAntagonist Open trials31 Perampanel Perampanel SponsorCatalyst Pharmaceuticals ModalitySmall molecule ActionAntagonist Open trials9 Phase 212 Osavampator Osavampator SponsorNeurocrine Biosciences ModalitySmall molecule ActionPositive allosteric modulator Open trials4 Becampanel Becampanel SponsorNot known ModalitySmall molecule ActionAntagonist Open trials0 CX1739 CX1739 SponsorNot known ModalityOther ActionPositive allosteric modulator Open trials0 Dasolampanel Dasolampanel SponsorNot known ModalitySmall molecule ActionAntagonist Open trials0 Farampator Farampator SponsorNot known ModalitySmall molecule ActionPositive allosteric modulator Open trials0 Irampanel Irampanel SponsorNot known ModalitySmall molecule ActionAntagonist Open trials0 Mibampator Mibampator SponsorEli Lilly ModalitySmall molecule ActionPositive allosteric modulator Open trials0 MK-8777 MK-8777 SponsorMerck & Co. (MSD) ModalityOther ActionPositive allosteric modulator Open trials0 Pesampator Pesampator SponsorBiogen ModalitySmall molecule ActionPositive allosteric modulator Open trials0 Selurampanel Selurampanel SponsorNovartis Pharmaceuticals ModalitySmall molecule ActionAntagonist Open trials0 Tezampanel anhydrous Tezampanel anhydrous SponsorTorreyPines Therapeutics ModalitySmall molecule ActionAntagonist Open trials0 Zonampanel Zonampanel SponsorAstellas Pharma ModalitySmall molecule ActionAntagonist Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 8 of 14 act as: Glutamate receptor ionotropic AMPA antagonist; the rest name their own mechanism. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 20 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s Topiramate Phase 4 Not yet recruiting Jing Luo Sep 21, 2026 Discontinuing Psychotropic Medication Before Psychotherapy for PTSD Topiramate — Not yet recruiting Academic Centre for Dentistry in Amsterdam Sep 3, 2026 Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma Topiramate Phase 2 Not yet recruiting St. Jude Children's Research Hospital Aug 27, 2026 Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy Topiramate Not applicable Not yet recruiting Phenomix Sciences Jul 27, 2026 Idiopathic Intracranial Hypertension: Prognostic Factors and Multidisciplinary Management Topiramate Not applicable Active, not recruiting Sohag University Jul 16, 2026 Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) Topiramate Phase 4 Not yet recruiting Stanford University Jun 17, 2026 Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation Topiramate — Recruiting Brai²n Feb 17, 2026 Combining Latency Reversing Agents to Address the HIV Reservoir Topiramate Phase 1 / Phase 2 Not yet recruiting Erasmus Medical Center Feb 3, 2026 Senicapoc and Perampanel for Newly Diagnosed Glioblastoma Perampanel Early phase 1 Recruiting Aarhus University Hospital Dec 16, 2025 A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Osavampator Phase 3 Recruiting Neurocrine Biosciences Sep 29, 2025 NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Osavampator Phase 3 Recruiting Neurocrine Biosciences May 8, 2025 NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Osavampator Phase 3 Recruiting Neurocrine Biosciences Apr 4, 2025 Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Osavampator Phase 3 Recruiting Neurocrine Biosciences Jan 22, 2025 A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures Perampanel — Recruiting Eisai Co., Ltd. Oct 24, 2024 PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest Perampanel Phase 2 Recruiting University of California, San Francisco May 7, 2024 Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Perampanel Phase 1 Recruiting Yale University Jun 22, 2023 The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects Perampanel Phase 2 Recruiting Yale University Mar 27, 2023 Antiepileptic Drugs in Elderly Patients Perampanel — Recruiting Wei Zhao Jul 15, 2022 Implantable Microdevice In Primary Brain Tumors Perampanel Early phase 1 Recruiting Oliver Jonas Oct 23, 2019 A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy Perampanel Phase 2 Active, not recruiting Eisai Inc. Jul 10, 2019
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2096670 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets